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Abstract The hemodynamic, mechanical and electrical
effects of cardiac resynchronization therapy (CRT) occur
immediate and are lasting as long as CRT is delivered.
Therefore, it is reasonable to assume that acute
hemodynamic effects should predict long-term outcome.
However, in the literature there is more evidence against
than in favour of this idea. This raises the question of
what factor(s) do relate to the benefit of CRT. There is
increasing evidence that dyssynchrony, presumably
through the resultant abnormal local mechanical behaviour,
induces extensive remodelling, comprising structure, as
well as electrophysiological and contractile processes.
Resynchronizationhasbeenshowntoreversetheseprocesses,
even in cases of limited hemodynamic improvement. These
data may indicate the need for a paradigm shift in order to
achieve maximal long-term CRT response.
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Introduction
The hemodynamic, mechanical and electrical effects of
cardiac resynchronization therapy (CRT) can be seen on
a beat-to-beat basis. They are immediate and last as long
as CRT is delivered. Changes in electrical conduction can
be easily appreciated on surface ECG or using more
sophisticated three-dimensional electroanatomical mapping
techniques, whereas changes in hemodynamics can be easily
monitored by systolic blood pressure, pulse pressure, stroke
volume and maximum rate of rise or decay of left ventricular
(LV) pressure (LV dP/dtmax or LV dP/dtmin). Finally,
changes in regional contraction pattern are immediately
visible by different cardiac imaging techniques, conventional
echocardiography, Doppler echocardiography and advanced
echocardiographic techniques (speckle tracking and tissue
Doppler imaging) being most commonly used methods in
clinical practice.
Given the on–off effect of CRT on different cardiac
components, investigators have measured LV dP/dtmax or
PV loops invasively [1–5], blood pressure [2, 6] and/or
stroke volume for guiding best pacing site [6–8] and, as
recommended by current clinical practice guidelines of the
European Society of Cardiology, for the selection of the
most optimal AV and VV delay [3, 6, 9, 10].
However, evidence in pre-clinical studies for a strong
relation between acute hemodynamic response and long-term
outcome is missing, and results in patients are conflicting.
One study comprising 33 patients demonstrated that
patients showing a large (>11%) increase in LV dP/dtmax
upon CRT have a greater probability of showing reverse
remodelling, defined asa significant reduction of LV volumes
[8]. These results are, however, not supported by several
other studies, including larger numbers of patients. In the
PATH-CHF study an acute increase in LV dP/dtmax did not
relate to a reduction in LV end-systolic volume [11]. A
similar disagreement between acute hemodynamic response
and reverse remodelling was also observed by Mullens et al.,
who showed that in a subset of patients deleterious cardiac
enlargement may occur despite a beneficial hemodynamic
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DOI 10.1007/s12265-011-9331-xeffect of CRT [12]. More recently two large studies
including a total of more than 350 patients found no relation
between the acute increase in LV dP/dtmax and survival
(or heart transplant; LVAD implant) [13, 14].
The puzzling absence of more positive findings, even
assuming a publication bias against reporting negative data,
suggests that acute hemodynamic response may only poorly
relate to long-term outcome of the patient. It raises at least
three major questions:
– Why is there a mismatch between acute hemodynamic
response and long-term outcome?
– What is the mechanism of CRTif improved hemodynamics
is not the main trigger of long-term benefit?
– What parameter should be considered appropriate to
acutely optimize CRT, if hemodynamic measures are
not reliable?
Possible Causes of the Mismatch
A trivial answer to the potential missing link between acute
hemodynamic response and long-term outcome is that heart
failure is a disease with a highly variable clinical course.
The latter may be considered a significant confounder to the
assessment, even if a relation between acute hemodynamic
effect and long-term response exists. Additional uncertainty
in predicting patient outcome is due to the influence of
co-morbidities or other medical conditions on the natural
course of the underlying disease.
At r u e“missing link” is the placebo effect, or better,
the psychological effect created by CRT, leading to
subjective improvement of health condition even in
“physiological non-responders”. In population-based
studies with other implantable devices, the placebo
effect has been shown to be considerable [15, 16].
Nevertheless, if hemodynamics would really play a role in
long-term outcome, one would expect a clearer relation
than demonstrated until now.
A pathophysiological clue to the acute–chronic mismatch
is that CRT gives rise to an acute effect, which is,
especially in good “responders”,f o l l o w e db yaf u r t h e r
increase in long-term benefit. This has been observed in
experimental LBBB [17] and in patients [18]. The
improvement appears to continue even over a period of
years as consistently shown in both observational and
controlled trials [19] These observations are interesting
and relevant, because treatment with drugs frequently
shows a saturation effect, causing a levelling off of the
beneficial effect, which requires additional therapy or a
higher dose of the same drug. Thinking along these lines,
if the acute hemodynamic response to CRT were the only
or the predominant effect, it would be expected to have a
saturating effect rather than to elicit a continuing improve-
ment. Thus, the fact that continuing improvement is
observed implies that other mechanisms are likely
involved. Also, in some hemodynamic non-responders
molecular remodelling has been observed.
It is also important to note that in order to have a good
prediction between acute hemodynamic effect and chronic
response to CRT, the accuracy of measurement during the
acute phase should be high enough and the spontaneous
variability of the parameter should be limited. As recently
pointed out, there is significant difficulty in clinical practice
to collect data accurate enough [20].
Finally, a good example to demonstrate the mismatch
between acute and chronic effect of CRT is given by the
reversal of maladaptive remodelling process which is a very
complex process including profound effect at molecular,
cellular and structural level. During the last decade a
number of studies have elucidated processes involved in
such cellular and molecular remodelling in dyssynchronous
hearts, predominantly in experimental models (see the next
section). Note that in clinical practice “reverse remodelling”
usually refers to a decrease in LV volume(s) given the
inability to routinely assess in vivo the effect of reverse
remodelling on other parameters.
Remodelling processes are initiated by triggers, frequently
more than one. For example, in hypertension the high blood
pressure is a clear trigger, but also the elevated plasma levels
of hormones like angiotensin play a role in changes at the
cellular and molecular level [21, 22].
Based on the above reasoning the inability to find a
link between acute hemodynamic effect and clinical
response to CRT is not unexpected, and given the
complex interplay of electrical, hemodynamic, mechanical
and structural factors, no single parameter will likely predict
chronic outcome after CRT. Nevertheless, understanding of
processes related to remodelling in the dyssynchronous
h e a r ta n dr e v e r s er e m o d e l l i n gi nC R Tm a yg i v eu s
insights on how we may better predict outcome in CRT
patients and potentially identify those patients who will
have impressive volume changes after CRT (so-called
“super-responders”) and those who will not show
meaningful changes in volume or in ventricular function
(so-called “non-responders).
Remodelling in Dyssynchronous Hearts
When a heart switches from normal, synchronous activation
to abnormal, asynchronous activation, the first event to
occur is that the initially uniform contraction becomes
heterogeneous, leading to reduction in pump function. As a
consequence, similar to what happens after the onset of
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system become activated in an attempt to stabilize the
hemodynamic situation. A recent study showed that the
baroreflex alters activity within 5 s after changing the
activation sequence [23]. Sympathetic activation is probably
maintained during long-term asynchronous activation,
because elevated levels of catecholamines have been
measured in dogs during chronic ventricular pacing [24]
and greater systemic vascular resistance in patients during
ventricular pacing [25].
It has been shown that during ventricular pacing the
LV pressure–volume relations show a rightward shift,
indicating that the heart operates at a larger volume, thus
leading to global stretching of the muscle fibers, a known
stimulus for subsequent remodelling processes. These
aforementioned processes appear similar to what happens
after myocardial infarction; therefore, also remodelling
processes originating from these derangements may be
similar to those observed in hearts after myocardial
infarction. However, the heterogeneous contraction patterns
have unique characteristics that may relate to remodelling
processesthatappeartobehighlyspecificfordyssynchronous
hearts. During dyssynchrony contraction in the various
regions is not only out of phase, but also workload within
the ventricular wall becomes heterogeneously distributed,
low values being present in early-activated regions and
high values in late-activated regions [26–28]. The latter
changes are also reflected by changes in regional blood
flow and oxygen consumption [29, 30]. In the long run,
this redistribution of mechanical load within the ventricular
wall leads to asymmetric hypertrophy, as demonstrated in
dogs during LV pacing [31] and with LBBB [17]a sw e l la s
in patients with LBBB [32]. This asymmetric hypertrophy is
characterized by an overall increase of LV muscle mass that
is most pronounced in the latest-activated regions (the LV
lateral wall in case of LBBB).
Over the last 5 years a series of studies in the canine
model of LBBB, alone or in combination with tachypacing-
induced heart failure, as well as in the mouse heart after
chronic RV pacing [33] have been published that shed some
light into the changes at the cellular level in asynchronous
hearts. These changes are very complex, more or less
mimicking the asymmetry of the macroscopic hypertrophy
in dyssynchronous hearts. Expression of some genes and
proteins is depressed uniformly, while others show regional
differences in expression. Examples of uniformly depressed
genes and proteins are virtually all potassium channels,
several calcium channels and beta-adrenergic receptors
[34, 35]. The fetal gene program and apoptosis related
genes are activated uniformly in dyssynchronous failing
hearts.
In contrast, the L-type calcium channel and the transient
outward potassium current (Ito) show, in addition to overall
downregulation, most pronounced downregulation in the
late-activated regions [34]. In addition, in the late-activated
LV lateral wall, stress response kinases as well as
TNFalpha were upregulated [36], and the gap junction
protein connexin 43 showed lateralization, the latter being
associated with slowing down of conduction velocity [37].
Finally, in dyssynchronous failing hearts, myocardial
catecholamine levels rose in both anteroseptal and lateral
walls (slightly more in the lateral walls) [34, 35].
Altogether, these global and regional changes lead to a
complicated “molecular fingerprint” of remodelling in the
dyssynchronous heart. Importantly, some abnormalities
were not observed in synchronous heart failure (rapid
atrial pacing), thus highlighting the importance of the
discoordinate contraction in the pathophysiology of heart
failure.
To date, the exact triggers for the locally different
remodelling processes are incompletely understood. In
general, abnormal stretch (a surrogate for mechanical load)
can change expression of genes and proteins in isolated
cultured myocytes and can induce a hypertrophic
response (e.g. mass or volume increase, BNP expression)
[22, 38]. There is conflicting evidence as to whether this
cellular response depends on local myocardial angiotensin
production. Data from some investigators indicated that
angiotensin II plays a critical role as an autocrine or
paracrine factor in stretch-induced hypertrophy of cardio-
myocytes [22, 39], whereas another study showed that
stretch-induced hypertrophy was not blocked by the
angiotensin receptor blocker irbesartan [38].
A potentially confounding factor is the presence of
fibroblasts in the myocyte culture. Blaauw et al. took
special care that their culture was almost free from
fibroblasts. More recently they found that stretched fibro-
blasts produce factors that, added to unstretched myocytes,
can stimulate myocyte growth. Because myocardial stretch
will influence both myocytes and fibroblasts, these data
suggest that stretch-induced hypertrophy is a concerted
action of the various cell types in the myocardium, partly
mediated by paracrine neurohumoral factors (Blaauw et al.,
personal communication).
An important question in this respect is as to whether
drugs, like beta-blockers, ACE inhibitors and angiotensin
receptor blockers, that inhibit the neurohumoral response at
the global level also do so at the local level. This is an
important question, because virtually all CRT candidates
are treated with these drugs. Be that as it is, molecular
abnormalities have been observed in myocardial samples
taken from ventricles of CRT candidates [40, 41]. Some
of these abnormalities, like downregulation of SERCA,
alpha-MHC and upregulation of BNP, are partly normalized
within 4 months in CRT responders [40, 41]. In
contrast, CRT non-responders appear to have a distinctive
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are genotypically different. A recent study in CRT
patients showed that among the three most common
polymorphisms of the beta-1 and the beta-2 adrenergic
receptors, only beta-2 adrenoceptor Gln27Glu gene
polymorphism has a significant association with the
LV response to CRT, with Glu27 carriers showing a
better response to CRT [42]. Although the study does
not allow to infer mechanisms for these gene related
differences, it is interesting to note that a greater
improvement in LV function in Glu27 carriers has been
described also after beta-blocker therapy [42].
Patients with a favourable response to CRT also show
changes in myocardial gene expression, including an
increase in mRNA levels of alpha-myosin heavy chain
(MHC), sarcoplasmic reticulum calcium ATPase (SERCA),
a decrease in BNP mRNA levels and an increase in the ratio
of alpha-MHC/beta-MHC [40, 41], which recapitulate those
previously shown with beta-blocker therapy.
Reversal of Dyssynchrony-Induced Remodelling
In experimental LBBB where heart rate is maintained in the
physiological range, application of CRT could almost
completely recovers the normal geometry and asymmetric
hypertrophy, as determined by standard echocardiography
[9]. In studies in the tachycardia-induced heart failure,
resynchronization was applied by changing RV pacing to
BiV pacing, while keeping the heart rate high (>200 bpm).
This mode of resynchronization created only a minor
improvement in overall pump function. Yet, considerable
molecular changes were observed. First of all, CRT
normalized the abnormal distribution of expression of L-
type calcium channel, CaM Kinase II, TNFalpha and p38
[34]; this normalization process fits with the idea that the
local contraction pattern is a determinant of local gene
expression. However, even without a major increase in
pump function, uniformly depressed genes and proteins
recovered, such as Akt, BAD, Ik, SERCA and beta-MHC
[34, 43]. Moreover, CRT reduced myocardial catecholamine
levels, accompanied by increased expression of beta1-
adrenergic receptor expression [35]. Still, high heart rate
CRT did not result in complete normalization of molecular
factors, because Ito and several calcium channels (all
uniformly depressed during DHF) did not show any
recovery [34]. One could speculate that complete reversal
also requires complete hemodynamic recovery.
These data do show that the more uniform contraction
patterns during rapid BiV pacing can create significant
reverse molecular remodelling. In Fig. 1 the various
effects of CRT are depicted, and based on the data from
the tachy-CRT model, it is supposed that the normalization
of strain (stretch) results in both recovery of the locally
disturbed proteins and the global ones that do recover by
tachy-CRT as compared to tachy-LBBB or tachy-RV
pacing. Along the same lines, it could be supposed that
factors that do not recover from tachy-CRT may recover
with the clinically applied CRT, where a larger benefit of
pump function is achieved, either acutely or after longer
lasting CRT.
For the role of the various proteins involved in recovery
by experimental biventricular pacing at a high heart rate
(>200 bpm), it appears that these changes might improve
underlying myocyte contractile function (e.g. recovery of
calcium handling proteins and beta-adrenergic receptors),
fibrosis and apoptosis (TNFalpha and BAD) and may
reduce risk of cardiac arrhythmia (e.g. potassium and
calcium channels, involved in dispersion of APD). A
remarkable finding was that CRT upregulated RGS
proteins, suppressing inhibitory G-protein activity. This
upregulation was shown to be a unique feature of recovery
from dyssynchronous heart failure [40]. Therefore, the
aforementioned remodelling processes relate to functions
that are highly relevant to the cure and survival of
patients.
Some of the aforementioned animal data are supported
by observations in patients obtained by myocardial biopsies
or by circulating blood sample. D’Ascia et al. showed
significant reduction in collagen deposition and TNFalpha
immunoreaction at the cellular level and that cellular
apoptotic activity as detected by a nuclei marked with
Fig. 1 Schematic representation of the various effects of cardiac
resynchronization therapy (CRT). Below the grey text blocks molecular
effects are mentioned, as observed in the animal model of tachy-
biventricular pacing, a model where the switch from tachy-RV pacing
to tachy-biventricular pacing resulted in only minor hemodynamic
changes. In the text it is argued in more detail that the observed
changes in this model are primarily triggered by restoration of uniform
contraction and stretch at the local level rather than hemodynamic
improvement
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caspase-3 were substantially reduced after CRT [41].
Moreover, patients with effective CRT more frequently
display chronic enhancement of circulating apelin, a
secreted hormone that can block adverse remodelling and
has positive inotropic effects [44]. Circulating biomarkers of
extracellular matrix remodelling also accompany successful
CRT therapy, including decreases in tenascin-C and
metalloproteinases [45]. Chronic CRT also has anti-
inflammatory effects, reducing monocyte chemoattractant
protein-1, interleukin-8 and interleukin-6 [46].
Improvements in Myocardial Oxygenation
An additional factor potentially modifying cardiac function
on the long run may be the oxygen supply–demand status
of the heart. In many patients the myocardial oxygen supply
is not optimal. Dyssynchrony may drive the heart of such
patients to the limit of the coronary dilatory reserve or even
into hibernation. The latter could occur globally or locally.
The entire heart may encounter lower perfusion reserve,
because the dyssynchronous heart has reduced efficiency in
converting metabolic energy into mechanical energy. At the
local level, especially regions with the highest mechanical
load, the late-activated regions, it may operate at elevated
demand levels. Moreover, several studies indicate that the
prolonged systolic phase and shorter diastole may hamper
coronary perfusion that, after all, predominantly occurs
during diastole. This effect may especially be relevant at
higher heart rates [47].
Resynchronization on its turn has been shown to
increase overall mechano-energetic balance of the heart
[48]. Similarly, Mills et al. showed, for pacing at various
sites,thatthemostuniformcontractioncoincidedwithhighest
mechano-energetic efficiency. In addition, resynchronization
may reduce mechanical overload in late-activated regions
[49]. Finally, resynchronization prolongs the diastole period,
not only improving ventricular filling but also allowing
longer coronary perfusion.
All these effects may lead to an increase of myocardial
perfusion reserve, as demonstrated in patients [50]. While
sudden improvement in oxygen supply/demand may cause
an immediate improvement of contraction, in the case of
hibernation a slow recovery is expected. Moreover, lower
oxygen consumption may also lead to less formation of
oxygen radicals that can produce or promote myocardial
damage. These oxygenation related recovery processes
may not be considered as “reverse remodelling” processes,
but will certainly assist in recovery of the myocardium
upon CRT and might explain (in part) the continuing
improvement of cardiac function, even years after the
start of CRT.
Lessons from Other Therapies
In this regard it is also important to note that other
therapies also enhance beta-adrenergic signaling, increase
SERCA expression and downregulate NCX [51–53].
Such therapies, like angiotensin converting enzyme inhibi-
tion, beta-blockade and ventricular assist devices, usually
antagonize deleterious neurohormonal pathways and/or
reduce hemodynamic load. The fact that, except for
LVAD therapy, these therapies do not improve cardiac
pump function directly, while improving patient longevity,
also supports the notion that the remodelling, rather than
an increase in pump function, is most relevant for the
long-term outcome of patients. Notably, these treatments
also improve oxygenation or reduce oxygen demand. In
contrast, positive inotropic agents, though improving pump
function, significantly increase mortality, again stressing the
mismatch between acute hemodynamic effect and long-term
outcome in heart failure [4–6, 54, 55]. Inotropes typically
stimulate an already inefficient and failing heart to further
increase its energy expenditure [56, 57], likely contributing
to the adverse impact of these drugs.
Therefore, while initially paradoxical, the mismatch
between acute hemodynamic response and long-term
outcome in patients is in agreement with experiences in
other therapies.
Does Non-Uniformity Relate to Long-Term Outcome?
In the literature mechanical dyssynchrony is defined in
various ways. Most commonly used are indices that use
time to onset or time to peak shortening in the various wall
segments. While various studies suggested a good relation
with CRT response (usually reverse remodelling after
6 months), other studies, including a few randomized
multicentre studies, were not able to reproduce these results
[58].
Alternatively, several groups have developed indices
that relate to differences in amplitude of shortening
between regions (“discoordination indices”). Several of
the latter studies showed that CRT response is quite
well predicted by a strong mechanical discoordination
[59, 60, 27]. However, these studies did not compare the
hemodynamic response with long-term outcome or wheth-
er optimal pump function is indeed achieved during
optimal mechanical recoordination.
Unsolved Questions
While an important role for reverse remodelling processes
at the molecular and cellular level may well be linked to
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answered. First of all, if hemodynamic response does not
relate to long-term outcome and mechanical recoordination
does, this may imply that optimal hemodynamic function is
not achievedatoptimal recoordination. This has,tothe bestof
our knowledge, not been studied nor is it well understood.
Furthermore, if recoordination of contraction is the main
trigger for reverse remodelling and survival, this would
imply that strain (or related) measurements should play a
more important role in application of CRT, both in selection
of patients and in selecting the best pacing sites and optimal
AV and VV intervals. While strain measurements are
becoming more feasible due to the introduction of speckle
tracking, this technique can only provide data by off-line
analysis. Therefore, while theoretically potentially quite
valuable, in daily practice the above ideas may be
challenging to apply. Clearly, more research and further
development of technology may be required.
Conclusions
Evidence is increasing that asynchrony can lead to major
and distinctive types of remodelling within the ventricular
wall, involving processes that might affect long-term
outcome. This remodelling is more closely associated with
the abnormal contraction pattern rather than to global
hemodynamics. Theoretical and practical implications of
this hypothesis remain to be proven.
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